AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06611683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: A threshold inspiratory muscule device used a starting resistance set at 30% maximum inspiratory pressure, connecting to subject artificial airway. The subjects were then instructed to perform fast and forceful inspirations against added inspiratory resistance. The inspiratory muscle training was conducted twice daily over five consecutive days, followed by a two-day rest period. This regimen continued for three consecutive weeks or until the subject no longer required ventilator support.
Study NCT06611683 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Routine care
Description: Subjects received routine care without intervention.
Study NCT03417037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Administered orally daily, 100 mg
Study NCT03417037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03417037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Platinum-based doublet chemotherapy
Study NCT01372202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Paclitaxel and cisplatin:~* Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.~* Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.~* Cisplatin 75 mg/m² days 1, 29.
Study NCT03858725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-374 5mg Tab.
Description: CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition
Study NCT01089764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couplelinks.ca website
Description: Participation in the Couplelinks.ca program, an online intervention.
Study NCT03917316 — intervention group
Intervention type: OTHER
Intervention: Language and neuropsychological tests
Description: Tests related to language, narrative and specific and general cognitive function
Study NCT03417037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Platinum-based doublet chemotherapy
Study NCT01372202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2 days 1, 15, 29.
Study NCT01372202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Oxaliplatin and 5-fluorouracil:~* Oxaliplatin 85 mg/m2 days 1, 15, 29.~* 5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.~* Cisplatin 75 mg/m² days 1, 29.
Study NCT00608725 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: DAXOR
Description: 131-I-Human Serum Albumin Blood Volume Assessment Kit
Study NCT00608725 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: QSweat
Description: Quantitative Sweat Testing
Study NCT00608725 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intrinsic Heart Rate
Description: Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
Study NCT04222062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine 7.7Mg Wafer
Description: GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.
Study NCT06625164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: core stabilization exercises
Study NCT04159519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort®
Description: Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.
Study NCT04159519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasenra®
Description: Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.
Study NCT04159519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ventolin®
Description: Participants will receive Salbutamol sulfate 100 μg per inhalation as needed.
Study NCT00441376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox
Description: 15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000. Administered as single dose intravenously over 30 minutes. Dose is determined by dose cohort patient enters study.
Study NCT05002673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DENTAL LOCAL ANESTHESİA
Description: doing local and topical anesthesia with two different device
Study NCT03604679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB C-0501
Description: Specified dose on specified days
Study NCT02775149 — intervention group
Intervention type: OTHER
Intervention: Collection of saliva samples
Description: Collection of saliva samples
Study NCT02775149 — intervention group
Intervention type: OTHER
Intervention: Visual detection of BEWE-index
Description: Visual detection of BEWE-index
Study NCT02222311 — intervention group
Intervention type: OTHER
Intervention: Blood Samples
Study NCT03031249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
Study NCT03031249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
Study NCT03031249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid
Description: ATRA at a dose of 30mg/㎡/d on day 1-14.
Study NCT01372202 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.
Study NCT03031249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: ATO at a dose of 10mg/d on day 1-14
Study NCT00576160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PST therapy
Description: Problem-Solving Therapy (PST) is a behavioral approach that teaches patients how to systematically solve their own behavioral difficulties. During telephone treatment sessions, the patient will discuss the problems and difficulties they face and that give rise to medication non-adherence.
Study NCT02901743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root planing
Description: All the patients were asked to use a preprocedural mouthrinse and scaling and rootplaning was done using ultrasonic scalers.
Study NCT02924389 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dolutegravir
Description: Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 50 mg of Tivicay (dolutegravir) will be taken orally once a day.
Study NCT02836379 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02171338 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PCT-level
Description: PCT-level is available to the treating doctor.
Study NCT02171338 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Antibiotic treatment based on PCT-level
Description: PCT-level is available to the treating doctor and the decision whether or not to treat with antibiotic is based on the level of PCT.~The type of antibiotic chosen to treat is based on the existing antibiotic treatment guidelines of Holbaek Hospital and includes the antibiotics listed above.
Study NCT01542723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH
Description: Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).
Study NCT01369030 — intervention group
Intervention type: OTHER
Intervention: Deplin®
Description: Deplin® is an orally administered medical food available in a 7.5mg tablet or a 15mg caplet with each containing either 7.5mg or 15mg of L-methylfolate, respectively - which is the primary biologically active and immediately bioavailable form of folate. Dosage for this study will be 1 15mg caplet QD.
Study NCT01372202 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: The type of resection (Ivor-Lewis, Transhiatal, etc.) will be left to the discretion of the operating surgeon. Resection will be completed between 5 and 8 weeks starting from the completion of chemotherapy and radiation (days 36 - 56).
Study NCT02924389 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triumeq
Description: Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine. Triumeq will be taken orally once daily.
Study NCT02924389 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Truvada
Description: Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily.
Study NCT04141891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Driving Decision Aid
Description: Healthwise DDA
Study NCT04141891 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Older Drivers Website
Description: National Institute on Aging (NIA) Older Drivers Website
Study NCT00979875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Study NCT00979875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Study NCT00979875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Study NCT00979875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Study NCT01146379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive task-specific upper extremity rehabilitation
Description: The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
Study NCT03456206 — intervention group
Intervention type: OTHER
Intervention: Intake of red and processed meat and fibres
Description: The intention is to analyse exposure groups in tertiles: 1) Upper tertile (33.3% of the total sample) based on the ratio: meat/fibre intake is associated with higher risk of CID. 2) Low intake of fibre (defined as below the lower tertile \[33.3% of the total sample\]) and high intake of red and processed meat (defined as those above the upper tertile \[33.3% of the total sample\]) are independently associated with higher risk of CID, and their synergy (interaction between the factors meat and fibres) gives the highest risk outcome.
Study NCT03456206 — intervention group
Intervention type: OTHER
Intervention: Lifestyle factors independently or combined
Description: Lifestyles factors are defined as: red and processed meat, vegetables, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/fat, protein/fat from red and processed meat, glycemic index.
Study NCT00789932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: 32 weeks of CBT, 1.5 hours weekly.
Study NCT00789932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual community care
Description: 16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
Study NCT00184496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: To methods for switching morphine to methadon. Stop-and go versus overlap
Study NCT03455569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral sleep education
Description: This group will receive manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
Study NCT03455569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education only
Description: This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
Study NCT04223635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.
Study NCT01432912 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Physician Educational Seminar
Description: Participating Physicians will attend an hour long seminar on smoking cessation counselling.
Study NCT03879980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilateral QL block
Description: Bilateral lateral Quadratus Lumborum block using 20 ml of 0.25% bupivacaine each injection as preemptive analgesia.
Study NCT03879980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-QL block
Description: Only received fentanyl IV during surgery.
Study NCT01287949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, polio and pertussis vaccination
Description: 1 dose of REPEVAX (0.5 mL) at Day 0, 1 dose of REVAXIS (0.5 mL) 1 month later and 1 dose of REVAXIS 6 month later
Study NCT02989649 — intervention group
Intervention type: DRUG
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT02989649 — intervention group
Intervention type: DRUG
Intervention: Alogliptin FDC With Pioglitazone
Description: Alogliptin FDC with pioglitazone tablets
Study NCT02989649 — intervention group
Intervention type: DRUG
Intervention: Alogliptin FDC With Metformin
Description: Alogliptin FDC with metformin tablets
Study NCT01966068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyAsthma Web Portal
Description: Parents will log on to the MyAsthma Web Portal up to three different times over a 6 month period. During each portal visit, parents will be asked to complete a survey which will include questions regarding their views on treatment preferences, goals, asthma control, and medications for their child with asthma.
Study NCT02195622 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lumenis VersaCut Morcellator
Study NCT02195622 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wolf Piranha Morcellator
Study NCT04490044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Under & Over rehabilitation tool
Description: Under \& Over is a tool consisting of a 40cm x 40cm white plastic board, two coloured laces and a series of patterns to complete. It enables people to create patterns by threading each lace under, and over the board. It has been designed and developed with people whose upper limb function is affected by their MS. Administration time can be dependent on the person completing it.
Study NCT04490044 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Under & Over rehabilitation tool
Description: Under \& Over is a tool consisting of a 40cm x 40cm white plastic board, two coloured laces and a series of patterns to complete. It enables people to create patterns by threading each lace under, and over the board. It has been designed and developed with people whose upper limb function is affected by their MS. Administration time can be dependent on the person completing it.
Study NCT02886234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Description: Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
Study NCT02886234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Coaching (HC)
Description: The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
Study NCT03504371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral erector spinae block
Description: The patient placed in a lateral position and transducer placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony acoustic shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side and preformed in the same way to achieve sensory block T5-T10 .
Study NCT03504371 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Thoracic epidural anesthesia
Description: patients will receive TEA where an epidural catheter will be placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine with 1:200,000 epinephrine will be injected followed by 5-6 ml of bupivacaine 0.25%.
Study NCT06768502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Based Approach (CBA)
Description: The community-based approach on IPV and sexual violence is conceived as a dynamic process where community members willing to recover from life wounds induced by IPV and sexual violence agree to share their lived experiences in order to work on them accordingly and to support each other in this healing journey.
Study NCT02825719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Description: Ulipristal acetate 5mg daily will be prescribed
Study NCT00624195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA Approved Antiretroviral Therapy (see list below)
Description: Combinations of FDA approved antiretroviral agents:~Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress~Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir
Study NCT00624195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA Approved Antiretroviral Therapy (see list below)
Description: Combinations of FDA approved antiretroviral agents:~Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress~Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir
Study NCT03413956 — intervention group
Intervention type: PROCEDURE
Intervention: Surgeries
Description: Surgeries
Study NCT03486678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210+GEMOX
Description: 28 days as a treatment cycle, SHR-1210 3mg/kg and Gemcitabine 800 mg/m2 will be administered IV Q2W (D1 and D15 of a treatment cycle),and Oxaliplatin 85mg/m2 will be administered IV Q2W (D2 and D16 of a treatment cycle). PD-1 antibody combined chemotherapy used up to 6 cycles.SHR-1210 3mg/kg IV Q2W will be administered beyond chemotherapy until the disease progression or untolerable toxicity.
Study NCT01532843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN alfa-2b
Description: Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks